SEARCH

SEARCH BY CITATION

References

  • 1
    Paumgartner G, Longueville J, Leevy CM. Phagocytic activity in experimental liver injury. Exp Mol Pathol 1968; 9: 161170.
  • 2
    Paumgartner G, Longueville J, Leevy CM. Phagocytic activity and hepatic function following localized proton radiation to the liver. Aerosp Med 1967; 38: 248251.
  • 3
    Leevy CM, Smith F, Longueville J, Paumgartner G, Howard MM. Indocyanine green clearance as a test for hepatic function. JAMA 1967; 200: 236240.
  • 4
    Paumgartner G, Huber J, Grabner G. Kinetik der hepatischen farbstoffaufnahme von indocyaningruen. Einfluss von bilirubin und natriumglykocholat [in German]. Experientia 1969; 25: 12191223.
  • 5
    Paumgartner G, Probst P, Kraines R, Leevy CM. Kinetics of indocyanine green removal from the blood. Ann N Y Acad Sci 1970; 170: 134146.
  • 6
    Paumgartner G. The handling of indocyanine green by the liver. Schweiz Med Wochenschr 1975; 105: 130.
  • 7
    Ohwada S, Kawate S, Hamada K, Yamada T, Sunose Y, Tsutsumi H, et al. Perioperative real-time monitoring of indocyanine green clearance by pulse spectrophotometry predicts remnant liver functional reserve in resection of hepatocellular carcinoma. Br J Surg 2006; 93: 339346.
  • 8
    Sakka SG. Assessing liver function. Curr Opin Crit Care 2007; 13: 207214.
  • 9
    Morris-Stiff G, Gomez D, Prasad R. Quantitative assessment of hepatic function and its relevance to the liver surgeon. J Gastrointest Surg 2009; 13: 374385.
  • 10
    Olmedilla L, Perez-Pena JM, Ripoll C, Garutti I, de Diego R, Salcedo M, et al. Early noninvasive measurement of the indocyanine green plasma disappearance rate accurately predicts early graft dysfunction and mortality after deceased donor liver transplantation. Liver Transpl 2009; 15: 12471253.
  • 11
    Horak W, Grabner G, Paumgartner G. Inhibition of bile salt-independent bile formation by indocyanine green. Gastroenterology 1973; 64: 10051012.
  • 12
    Paumgartner G, Grabner G. Das verhalten konjugierter gallensaueren des serums bei erkrankungen der leber [in German]. Acta Hepatosplenol 1969; 17: 344353.
  • 13
    Paumgartner G, Grabner G, Brunner H, Hauth K. Die serumkonzentrationen konjugierter gallensaeuren beim nichthaemolitischen ikterus [in German]. Wien Z inn Med 1969; 50: 171176.
  • 14
    Paumgartner G, Schnack H, Seifert E, Wewalka F. Die indocyaningruen-clearance beim Dublin-Johnson-Syndrom [in German]. Z Gastroenterol 1969; 7: 384389.
  • 15
    Reichen J, Paumgartner G. Kinetics of taurocholate uptake by the perfused rat liver. Gastroenterology 1975; 68: 132136.
  • 16
    Paumgartner G, Reichen J. Different pathways for hepatic uptake of taurocholate and indocyanine green. Experientia 1975; 31: 306307.
  • 17
    Paumgartner G, Reichen J. Kinetics of hepatic uptake of unconjugated bilirubin. Clin Sci Mol Med 1976; 51: 169176.
  • 18
    Reichen J, Paumgartner G. Uptake of bile acids by perfused rat liver. Am J Physiol 1976; 231: 734742.
  • 19
    Minder E, Paumgartner G. Disparate Na+-requirement of taurocholate and indocyanine green uptake by isolated hepatocytes. Experientia 1979; 35: 888890.
  • 20
    Paumgartner G, Herz R, Sauter K, Schwarz HP. Taurocholate excretion and bile formation in the isolated perfused rat liver. An in vitro -in vivo comparison. Naunyn Schmiedebergs Arch Pharmacol 1974; 285: 165174.
  • 21
    Herz R, Paumgartner G, Preisig R. Inhibition of bile formation by high doses of taurocholate in the perfused rat liver. Scand J Gastroenterol 1976; 11: 741746.
  • 22
    von Bergmann K, Schwarz HP, Paumgartner G. Effect of phenobarbital, spironolactone and pregnenolone-16 alpha-carbonitrile on bile formation in the rat. Naunyn Schmiedebergs Arch Pharmacol 1975; 287: 3345.
  • 23
    Herz R, Paumgartner G, Preisig R. Bile salt metabolism and bile formation in the rat with a protacaval shunt. Eur J Clin Invest 1974; 4: 223228.
  • 24
    Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217225.
  • 25
    Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004; 126: 322342.
  • 26
    Hagenbuch B, Dawson P. The sodium bile salt cotransport family SLC10. Pflugers Arch 2004; 447: 566570.
  • 27
    Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 2003; 1609: 118.
  • 28
    Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001; 276: 96269630.
  • 29
    Kullak-Ublick GA, Beuers U, Meier PJ, Domdey H, Paumgartner G. Assignment of the human organic anion transporting polypeptide (OATP) gene to chromosome 12p12 by fluorescence in situ hybridization. J Hepatol 1996; 25: 985987.
  • 30
    Kullak-Ublick GA, Beuers U, Fahney C, Hagenbuch B, Meier PJ, Paumgartner G. Identification and functional characterization of the promoter region of the human organic anion transporting polypeptide gene. HEPATOLOGY 1997; 26: 991997.
  • 31
    Stieger B, Meier Y, Meier PJ. The bile salt export pump. Pflugers Arch 2007; 453: 611620.
  • 32
    Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 2007; 453: 643659.
  • 33
    Kartenbeck J, Leuschner U, Mayer R, Keppler D. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. HEPATOLOGY 1996; 23: 10611066.
  • 34
    Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. HEPATOLOGY 1997; 25: 15391542.
  • 35
    Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003; 83: 633671.
  • 36
    Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm 2006; 3: 231251.
  • 37
    Paumgartner G. Medical treatment of cholestatic liver diseases: from pathobiology to pharmacological targets. World J Gastroenterol 2006; 12: 44454451.
  • 38
    Paumgartner G, Pusl T. Medical treatment of cholestatic liver disease. Clin Liver Dis 2008; 12: 5380.
  • 39
    Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J Hepatol 2009; 51: 565580.
  • 40
    Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001; 276: 2885728865.
  • 41
    Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002; 277: 29082915.
  • 42
    Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. HEPATOLOGY 2009; 49: 12281235.
  • 43
    Mannes GA, Thieme C, Stellaard F, Wang T, Sauerbruch T, Paumgartner G. Prognostic significance of serum bile acids in cirrhosis. HEPATOLOGY 1986; 6: 5053.
  • 44
    Paumgartner G, Sauerbruch T. Gallstones: pathogenesis. Lancet 1991; 338: 11171121.
  • 45
    Paumgartner G, Greenberger N. Gallstone disease. In: GreenbergerN, BlumbergRS, BurakoffR, eds. Current Diagnosis and Treatment: Gastroenterology, hepatology, endoscopy. New York: McGraw-Hill; 2009: 537546.
  • 46
    Yu L, Hammer RE, Li-Hawkins J, Von Bergmann K, Lutjohann D, Cohen JC, et al. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci U S A 2002; 99: 1623716242.
  • 47
    Yu L, Gupta S, Xu F, Liverman AD, Moschetta A, Mangelsdorf DJ, et al. Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem 2005; 280: 87428747.
  • 48
    Nilsell K, Angelin B, Liljeqvist L, Einarsson K. Biliary lipid output and bile acid kinetics in cholesterol gallstone disease. Evidence for an increased hepatic secretion of cholesterol in Swedish patients. Gastroenterology 1985; 89: 287293.
  • 49
    Marschall HU, Einarsson C. Gallstone disease. J Intern Med 2007; 261: 529542.
  • 50
    Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall HU. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. HEPATOLOGY 2005; 41: 11381143.
  • 51
    Grunhage F, Acalovschi M, Tirziu S, Walier M, Wienker TF, Ciocan A, et al. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. HEPATOLOGY 2007; 46: 793801.
  • 52
    Buch S, Schafmayer C, Volzke H, Becker C, Franke A, von Eller-Eberstein H, et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet 2007; 39: 995999.
  • 53
    Marcus SN, Heaton KW. Deoxycholic acid and the pathogenesis of gall stones. Gut 1988; 29: 522533.
  • 54
    Stellaard F, Sackmann M, Sauerbruch T, Paumgartner G. Simultaneous determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnover rates in human serum using 13C-labeled bile acids. J Lipid Res 1984; 25: 13131319.
  • 55
    Stellaard F, Paumgartner G, van Berge Henegouwen GP, van der Werf SDJ. Determination of deoxycholic acid pool size and input rate using 24-13C deoxycholic acid and serum sampling. J Lipid Res 1987; 27: 12221225.
  • 56
    Stellaard F, Sackmann M, Berr F, Paumgartner G. Simultaneous determination of pool sizes and fractional turnover rates of deoxycholic acid, cholic acid and chenodeoxycholic acid in man by isotope dilution with 2H and 13C lables and serum sampling. Biomed Environ Mass Spectrom 1987; 14: 609611.
  • 57
    Berr F, Pratschke E, Fischer S, Paumgartner G. Disorders of bile acid metabolism in cholesterol gallstone disease. J Clin Invest 1992; 90: 859868.
  • 58
    Berr F, Kullak-Ublick GA, Paumgartner G, Munzing W, Hylemon PB. 7 alpha-dehydroxylating bacteria enhance deoxycholic acid input and cholesterol saturation of bile in patients with gallstones. Gastroenterology 1996; 111: 16111620.
  • 59
    Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL. Dissolution of cholesterol gallstones by chenodeoxycholic acid. N Engl J Med 1972; 286: 18.
  • 60
    Hofmann AF, Paumgartner G. Chenodeoxycholic Acid Therapy of Gallstones. Stuttgart, Germany: F.K. Schattauer; 1974.
  • 61
    Paumgartner G. Pharmacokinetic aspects of chenodeoxycholic acid therapy. Hosp Pract 1975; 10: 117122.
  • 62
    Miescher G, Paumgartner G, Preisig R. Portal-systemic spill-over of bile acids: a study of mechanisms using ursodeoxycholic acid. Eur J Clin Invest 1983; 13: 439445.
  • 63
    von Bergmann K, Schultheiss HR, Paumgartner G, Preisig R. Die konjugation von chenodesoxycholsaeure und cholsaeure waehrend einer leberpassage [in German]. Schweiz Med Wochenschr 1975; 105: 413415.
  • 64
    Makino I, Shinozaki K, Yoshino K, Nakagawa S. Dissolution of cholesterol gallstones by long-term administration of ursodeoxycholic acid [in Japanese]. Jpn J Gastroenterol 1975; 72: 690702.
  • 65
    Nakagawa S, Makino I, Ishizaki T, Dohi I. Dissolution of cholesterol gallstones by ursodeoxycholic acid. Lancet 1977; 2: 367369.
  • 66
    Shimizu M. Gallstone dissolving agents. In: OdaT, MuraoS, KumagayaA, OkaH, eds. A Chapter of Histories of Treatments. Tokyo: Life Sci Publisher; 1986: 411418.
  • 67
    Sauerbruch T, Delius M, Paumgartner G, Holl J, Wess O, Weber W, et al. Fragmentation of gallstones by extracorporeal shock waves. N Engl J Med 1986; 314: 818822.
  • 68
    Sackmann M, Weber W, Delius M, Holl J, Hagelauer U, Sauerbruch T, et al. Extracorporal shock-wave lithotripsy of gallstones without general anesthesia: first clinical experience. Ann Intern Med 1987; 107: 347348.
  • 69
    Sackmann M, Delius M, Sauerbruch T, Holl J, Weber W, Ippisch E, et al. Shock-wave lithotripsy of gallbladder stones. The first 175 patients. N Engl J Med 1988; 318: 393397.
  • 70
    Sackmann M, Pauletzki J, Sauerbruch T, Holl J, Schelling G, Paumgartner G. The Munich Gallbladder Lithotripsy Study. Results of the first 5 years with 711 patients. Ann Intern Med 1991; 114: 290296.
  • 71
    Sackmann M, Eder H, Spengler U, Pauletzki J, Holl J, Paumgartner G, et al. Gallbladder emptying is an important factor in fragment disappearance after shock wave lithotripsy. J Hepatol 1993; 17: 6266.
  • 72
    Pauletzki J, Sailer C, Kluppelberg U, von Ritter C, Neubrand M, Holl J, et al. Gallbladder emptying determines early gallstone clearance after shock-wave lithotripsy. Gastroenterology 1994; 107: 14961502.
  • 73
    Paumgartner G. Nonsurgical management of gallstone disease. In: FeldmanM, FriedmanLS, SleisengerMH, eds. Gastrointestinal and Liver Disease. Volume 1. ed. 7. Philadelphia: Saunders; 2002: 11071115.
  • 74
    Sackmann M, Ippisch E, Sauerbruch T, Holl J, Brendel W, Paumgartner G. Early gallstone recurrence rate after successful shock-wave therapy. Gastroenterology 1990; 98: 392396.
  • 75
    Sackmann M, Niller H, Klueppelberg U, von Ritter C, Pauletzki J, Holl J, et al. Gallstone recurrence after shock-wave therapy. Gastroenterology 1994; 106: 225230.
  • 76
    Pauletzki J, Althaus R, Holl J, Sackmann M, Paumgartner G. Gallbladder emptying and gallstone formation: a prospective study on gallstone recurrence. Gastroenterology 1996; 111: 765771.
  • 77
    Berr F, Mayer M, Sackmann MF, Sauerbruch T, Holl J, Paumgartner G. Pathogenic factors in early recurrence of cholesterol gallstones. Gastroenterology 1994; 106: 215224.
  • 78
    Soehendra N, Nam VC, Binmoeller KF, Koch H, Bohnacker S, Schreiber HW. Pulverisation of calcified and non-calcified gall bladder stones: extracorporeal shock wave lithotripsy used alone. Gut 1994; 35: 417422.
  • 79
    Sauter G, Kullak-Ublick GA, Schumacher R, Janssen J, Greiner L, Brand B, et al. Safety and efficacy of repeated shockwave lithotripsy of gallstones with and without adjuvant bile acid therapy. Gastroenterology 1997; 112: 16031609.
  • 80
    Paumgartner G, Sauter GH. Extracorporeal shock wave lithotripsy of gallstones: 20th anniversary of the first treatment. Eur J Gastroenterol Hepatol 2005; 17: 525527.
  • 81
    Sauerbruch T, Stern M. Fragmentation of bile duct stones by extracorporeal shock waves. A new approach to biliary calculi after failure of routine endoscopic measures. Gastroenterology 1989; 96: 146152.
  • 82
    Sauerbruch T, Holl J, Sackmann M, Paumgartner G. Fragmentation of bile duct stones by extracoporeal shock-wave lithotripsy. A five-years experience. HEPATOLOGY 1992; 15: 208214.
  • 83
    Sackmann M, Holl J, Sauter GH, Pauletzki J, von Ritter C, Paumgartner G. Extracorporeal shock wave lithotripsy for clearance of bile duct stones resistant to endoscopic extraction. Gastrointest Endosc 2001; 53: 2732.
  • 84
    Ellis RD, Jenkins AP, Thompson RP, Ede RJ. Clearance of refractory bile duct stones with extracorporeal shockwave lithotripsy. Gut 2000; 47: 728731.
  • 85
    Adamek HE, Kudis V, Jakobs R, Buttmann A, Adamek MU, Riemann JF. Impact of gallbladder status on the outcome in patients with retained bile duct stones treated with extracorporeal shockwave lithotripsy. Endoscopy 2002; 34: 624627.
  • 86
    Lammert F, Neubrand MW, Bittner R, Feussner H, Greiner L, Hagenmuller F, et al. S3-guidelines for diagnosis and treatment of gallstones. German Society for Digestive and Metabolic Diseases and German Society for Surgery of the Alimentary Tract [in German]. Z Gastroenterol 2007; 45: 9711001.
  • 87
    Sauerbruch T, Holl J, Sackmann M, Werner R, Wotzka R, Paumgartner G. Disintegrtation of a pancreatic duct stone with extracorporeal shock waves in a patient with chronic pancreatitis. Endoscopy 1987; 19: 207208.
  • 88
    Sauerbruch T, Holl J, Sackmann M, Paumgartner G. Extracorporeal lithotripsy of pancreatic stones in patients with chronic pancreatitis and pain: A prospective follow up study. Gut 1992; 33: 969972.
  • 89
    Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci 1985; 30: 642649.
  • 90
    Miyai K, Akiyama T, Ito M, Urakawa T, Shimaji Y. The effect of ursodeoxycholic acid on liver function in patients with chronic liver disease. Rinsho to Kenkyu 1976; 53: 13951403.
  • 91
    Yamanaka M, Oto M, Obata H, Shimizu M, Sugata F, Hatta Y, et al. The examination of the therapeutic efficacy of ursodeoxycholic acid on chronic hepatitis. A double blind study. Shindan to Chiryo 1976; 64: 21502157.
  • 92
    Kitani K. Hepatoprotective effect of ursodeoxycholate in experimental animals. In: PaumgartnerG, StiehlA, BarbaraL, RodaE, eds. Strategies for the Treatment of Hepatobiliary Diseases. Lancaster, UK: Kluwer; 1990: 4356.
  • 93
    Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1: 834836.
  • 94
    Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. HEPATOLOGY 1992; 16: 707714.
  • 95
    Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324: 15481554.
  • 96
    Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691695.
  • 97
    Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 14641472.
  • 98
    Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. HEPATOLOGY 2009; 50: 808814.
  • 99
    Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002; 123: 12381251.
  • 100
    European Association for the Study of the Liver. Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol 2009; 51: 237267.
  • 101
    Leuschner U, Fischer H, Kurtz W, Guldutuna S, Hubner K, Hellstern A, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97: 12681274.
  • 102
    Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. HEPATOLOGY 1994; 19: 11491156.
  • 103
    Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 12841290.
  • 104
    Poupon RE, Chretien Y, Poupon R, Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. HEPATOLOGY 1993; 17: 599604.
  • 105
    Poupon RE, Lindor K, Pares A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effects of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39: 1216.
  • 106
    Paumgartner G. Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression. J Hepatol 2003; 39: 112114.
  • 107
    Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884890.
  • 108
    Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128: 297303.
  • 109
    Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130: 715720.
  • 110
    ter Borg PC, Schalm SW, Hansen BE, van Buuren HR. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006; 101: 20442050.
    Direct Link:
  • 111
    Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. HEPATOLOGY 2009; 50: 291308.
  • 112
    Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. HEPATOLOGY 1992; 15: 603608.
  • 113
    Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 318328.
  • 114
    Beuers U, Nathanson MH, Isales CM, Boyer JL. Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis. J Clin Invest 1993; 92: 29842993.
  • 115
    Beuers U, Nathanson MH, Boyer JL. Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes. Gastroenterology 1993; 104: 604612.
  • 116
    Beuers U, Throckmorton DC, Anderson MS, Isales CM, Thasler W, Kullak-Ublick GA, et al. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes. Gastroenterology 1996; 110: 15531563.
  • 117
    Beuers U, Bilzer M, Chittattu A, Kullak-Ublick GA, Keppler D, Paumgartner G, et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. HEPATOLOGY 2001; 33: 12061216.
  • 118
    Dombrowski F, Stieger B, Beuers U. Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab Invest 2006; 86: 166174.
  • 119
    Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005; 129: 476485.